Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2351MR)

This product GTTS-WQ2351MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ2351MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3958MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ7014MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA F-627
GTTS-WQ9787MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JS002
GTTS-WQ1026MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ8750MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ1706MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ10017MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA KRN-23
GTTS-WQ4595MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986015
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW